Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03387085 · ClinicalTrials.gov registry record · Phase 1
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
A Phase 1 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03387085: Clinical Trial Phase 1 study, sponsored by ImmunityBio.
NCT03387085 is a Phase 1 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03387085, a Phase 1 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with TNBC who have progressed on or after previous SoC chemotherapy. Phase 2 will be based on Simon's two-stage optimal design.
Primary Outcome
Graded using the NCI CTCAE Version 4.03.
Interventions
- BIOLOGICAL N-803
- DRUG Aldoxorubicin HCl
- BIOLOGICAL ETBX-011
- BIOLOGICAL ETBX-051
- BIOLOGICAL ETBX-061
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2024-01-16 |
| Phase | Phase 1 |
Why NCT03387085 stopped before completion
NCT03387085 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 5 interventions - of which N-803 is the first listed.
NCT03387085 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03387085 about?
NCT03387085 is a clinical study titled "QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.". This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with TNBC who have progressed on or after previous SoC chemotherapy. Phase 2 will be based on Simon's two-stage optimal design.
What is the current status of trial NCT03387085?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2018-03-19. Estimated completion is 2024-01-16.
What interventions are being tested in trial NCT03387085?
The interventions under investigation include: N-803 (BIOLOGICAL), Aldoxorubicin HCl (DRUG), ETBX-011 (BIOLOGICAL), ETBX-051 (BIOLOGICAL), ETBX-061 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03387085?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03387085's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI